LOS ANGELES, CA - March 9, 2026 (NEWMEDIAWIRE) - Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to the immune system. Researchers are increasingly focused on strategies that make tumors more visible and susceptible to immune attack, and LIXTE Biotechnology Holdings (NASDAQ: LIXT) is developing a compound designed to contribute to that effort. Its lead candidate, LB-100, targets a cellular enzyme involved in tumor biology and immune regulation, with the goal of enhancing responsiveness to existing cancer therapies.

  • The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells
  • LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents
  • The company is advancing LB-100 through clinical development in collaboration with academic and research institutions

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells. Drugs targeting immune checkpoints such as PD-1 and PD-L1 have delivered durable responses in melanoma, lung cancer and other malignancies. According to the National Cancer Institute, immune checkpoint inhibitors work by blocking proteins that prevent T cells from attacking…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law